Three-month paliperidone palmitate - a new treatment option for schizophrenia

References

• Owen MJ, Sawa A, Mortensen PB. Schizophrenia [Internet]. Lancet. 2016 [cited 2016 Jan 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26777917
   Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews. 2008;30(1):67–76.
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210.
   PubMed Web of Science ®Google Scholar
• Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153–160.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, Parker AG, Hetrick SE, et al. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011 May;37(3):619–630.
   Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16(1):34–45.
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53–66.
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr., Buchanan RW. Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia. JAMA Psychiatry. 2015;72(8):745–746.
   PubMed Web of Science ®Google Scholar
• Azorin JM. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia]. Encephale. 2013;39(Suppl 2):S121–123.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Bioque M. What have we learned from research into first-episode psychosis? Rev Psiquiatr Salud Ment. 2014;7(2):61–63.
   PubMed Web of Science ®Google Scholar
• Bioque M, Llerena A, Cabrera B, et al. A pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the PEPs project. Int J Neuropsychopharmacol. 2016 Mar 31;19(4). doi:10.1093/ijnp/pyv121.
   Google Scholar
• Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S7–S12.
   PubMedGoogle Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.
   PubMedGoogle Scholar
• Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47(5):741–773.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213.
   PubMed Web of Science ®Google Scholar
• Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv. 2016;13(2):253–264.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965.
   PubMed Web of Science ®Google Scholar
• Janssen. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension prescribing information. Titusville (NJ): Orth-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
   Google Scholar
• Nussbaum M, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;6:CD008296. doi:10.1002/14651858.CD008296.pub2.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. 2016. “FDA webpage.” Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
   Google Scholar
• Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Schizophrenia Bulletin. 2012;38(6):1124–1127.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez A, Catalan R, Penades R, et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review. Patient Prefer Adherence. 2015;9:695–706.
   PubMedGoogle Scholar
• Bossie CA, Sliwa JK, Ma YW, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry. 2011;11:79.
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2–3):107–117.
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218–226.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–2082.
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12.
   PubMed Web of Science ®Google Scholar
• Bossie CA, Fu DJ, Sliwa JK, et al. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol. 2011;1(4):111–124.
   PubMedGoogle Scholar
• Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002–1008.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107–118.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, et al. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. Clin Ther. 2014;36(10):1372–1388 e1371.
   PubMed Web of Science ®Google Scholar
• Zhang F, Si T, Chiou CF, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:657–668.
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561.
   PubMed Web of Science ®Google Scholar
• Hargarter L, Cherubin P, Bergmans P, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2015;58:1–7.
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016 May 2. [Epub ahead of print]
   PubMedGoogle Scholar
• Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–339.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72:830.
   PubMed Web of Science ®Google Scholar
• Kerbusch-Herben V, Cleton A, Berwaerts J, et al. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state. Clin Pharmacol Drug Dev. 2014;3(5):371–377.
   PubMed Web of Science ®Google Scholar
• Heres S, Reichhart T, Hamann J, et al. Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry. 2011;26(5):297–301.
   PubMed Web of Science ®Google Scholar
• Patel M, Haddad P, Chaudhry I, et al. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24(10):1473–1482.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Liu D, Ziebell S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609–615.
   PubMed Web of Science ®Google Scholar
• Leza JC, Garcia-Bueno B, Bioque M, et al. Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev. 2015;55:612–626.
   PubMed Web of Science ®Google Scholar
• Manchanda R, Chue P, Malla A, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry. 2013;58(5 Suppl 1):5S–S13.
   Google Scholar
• Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829.
   PubMed Web of Science ®Google Scholar
• Malla A, Tibbo P, Chue P, et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry. 2013;58(5 Suppl 1):30S–35S.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectrums. 2014;19(1):3–5.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
   PubMed Web of Science ®Google Scholar
• Sanz-Fuentenebro J, Taboada D, Palomo T, et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophr Res. 2013;149(1–3):156–161.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995–1003.
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Maia-Lopes S, Goswami P, et al. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. J Med Econ. 2016 May 13:1–9. [Epub ahead of print]
   Web of Science ®Google Scholar
• Zeidler J, Mahlich J, Greiner W, et al. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11(5):509–521.
   PubMedGoogle Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics. 2016;34:363–391.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecon Outcomes Res. 2015;7:267–272.
   PubMed Web of Science ®Google Scholar